How Will VeriSign Stock React To Its Upcoming Earnings?
VeriSign (NASDAQ:VRSN) is set to announce its earnings on Thursday, July 24, 2025. Over the last five years, VRSN stock has displayed an equal division in one-day returns following earnings announcements. The stock achieved a positive one-day return in 50% of cases, with a median increase of 2.9%. In contrast, it experienced a negative one-day return in the remaining 50% of cases, with a median drop of -2.7%.
While the actual results compared to consensus estimates will be essential, grasping these historical trends can offer an advantage for traders focused on events. There are two main strategies to utilize this information:
Analysts anticipate earnings of $2.20 per share on revenue of $410 million for the upcoming quarter. This would mark an increase compared to the earnings from the same quarter last year, which were $2.01 per share on sales of $387 million.
From a fundamental viewpoint, VeriSign currently has a market capitalization of $27 billion. Over the past twelve months, the company generated $1.6 billion in revenue, with operating earnings of $1.1 billion and a net income of $791 million, demonstrating strong operational profitability.
However, if you are looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — having outperformed the S&P 500 and achieved returns exceeding 91% since its launch. Also, take a look at – What's Happening With PepsiCo Stock?
View earnings reaction history of all stocks
Historical Probability of Positive Post-Earnings Returns for VeriSign
Here are some insights into one-day (1D) post-earnings returns:
Additional information regarding observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below.
5-Day (5D) and 21-Day (21D) returns post earnings
Correlation Among 1D, 5D, and 21D Historical Returns
A relatively lower-risk strategy (although not beneficial if the correlation is weak) involves understanding the relationship between short-term and medium-term returns after earnings, identifying pairs that exhibit the strongest correlation, and executing the appropriate trade. For instance, if 1D and 5D demonstrate the highest correlation, a trader can position themselves 'long' for the following 5 days if the 1D post-earnings return is positive. Here is some correlation data based on the 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and the subsequent 5D returns.
Correlation Among 1D, 5D, and 21D Historical Returns
Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a combination of all 3: the S&P 500, S&P mid-cap, and Russell 2000), delivering substantial returns for investors. Additionally, if you want upside with a smoother experience than an individual stock like VeriSign, consider the High Quality portfolio, which has outperformed the S&P and recorded >91% returns since its inception.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
KeyCorp Stock: Is Wall Street Bullish or Bearish?
Valued at a market cap of $19.9 billion, KeyCorp (KEY) is a financial services company that operates as the holding company for KeyBank National Association. It offers a broad range of retail and commercial banking products and services across the United States through its Consumer and Commercial Bank segments. The Cleveland, Ohio-based company's shares have underperformed the broader market over the past 52 weeks. KEY stock has increased 11.8% over this time frame, while the broader S&P 500 Index ($SPX) has rallied over 17%. Moreover, shares of KeyCorp are up 6% on a YTD basis, compared to SPX's 8.2% rise. More News from Barchart Morgan Stanley Says Nvidia Has 'Exceptional' Strength. Should You Buy NVDA Stock Here? Dear MicroStrategy Stock Fans, Mark Your Calendars for July 31 2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! In addition, KEY stock has lagged behind the Financial Select Sector SPDR Fund's (XLF) 20.2% return over the past 52 weeks. Shares of KeyCorp rose 2.4% on Jul. 22 following stronger-than-expected Q2 2025 results, with EPS of $0.35 beating the consensus estimate and marking a 40% year-over-year increase. Investor sentiment was boosted by a 20.9% rise in total revenues to $1.8 billion, driven by higher net interest income and a 10% increase in non-interest income, particularly from robust fee-based businesses. Additionally, improved capital ratios and sequential loan growth signaled financial strength, offsetting concerns over rising expenses and provisions. For the current fiscal year, ending in December 2025, analysts expect KeyCorp's EPS to grow 23.3% year-over-year to $1.43. The company's earnings surprise history is promising. It beat the consensus estimates in the last four quarters. Among the 23 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on 10 'Strong Buy' ratings, two 'Moderate Buys,' and 11 'Holds.' On Jul. 28, Truist raised KeyCorp's price target to $19 while maintaining a 'Hold" rating, citing increased expenses from hiring and tech investments alongside higher expected fees driven by strong investment banking momentum. As of writing, the stock is trading below the mean price target of $19.90. The Street-high price target of $22 implies a potential upside of 21.1% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run.
Key Points Palantir Technologies now ranks in the top 25 of the most valuable companies in the world. Its Artificial Intelligence Platform (AIP) is wildly popular for commercial and government clients. 10 stocks we like better than Palantir Technologies › There are probably few investors out there who are more satisfied than those who bought Palantir Technologies (NASDAQ: PLTR) stock early in its run. The artificial intelligence (AI) company is blowing other stocks out of the water these days, with its stock up 478% in the last year and more than doubling in 2025. Palantir is now one of the world's top 25 most valuable companies, ahead of such blue chip names as Procter & Gamble and Bank of America. Palantir's run is fueled by the adaptation of its Artificial Intelligence Platform (AIP) by government and commercial clients, fueling dramatic growth in both revenue and earnings. And with Palantir set to report second-quarter earnings on Aug. 4, there are plenty of reasons to believe that this run is far from over. How Palantir is making money Palantir already had two AI-powered platforms. Its Gotham platform is prized by governments and defense agencies to gather information from multiple sources, identify targets, and make real-time assessments to provide insights about battlefield situations. Palantir is recognized for helping the U.S. military track down 9/11 mastermind Osama bin Laden in 2011. Then you have the Foundry platform used by Palantir's commercial clients. Foundry helps clients manage supply chains and inventory, automate workflows, and optimize operations. The AIP platform made both of these powerful tools better and easier to use because AIP allows users to make detailed queries, and then it generates responses using generative AI. And the results are evident in the massive gains the company is seeing: Since rolling out AIP in April 2023, Palantir's revenues have gone through the roof. Year Revenue Profit (Loss) Earnings per Share 2021 $1.54 billion ($520.3 million) ($0.27) 2022 $1.90 billion ($161.2 million) ($0.18) 2023 $2.22 billion $217.3 million $0.10 2024 $2.86 billion $467.9 million $0.21 2025 (projected) $3.90 billion Image source: Palantir Technologies. In the first quarter of 2025, the company reported revenue of $884 million, up 39% from a year ago. U.S. commercial revenue jumped 71% from a year ago to $255 million, and U.S. government revenue was up 45% from a year ago to $373 million. The stock is by far outperforming the biggest companies on the planet, as well as the S&P 500 and the Nasdaq Composite. What can we expect from Palantir next? The second quarter is expected to be another blowout quarter. The company is continuing to reel in work, including contracts with the Navy to improve ship production and fleet readiness and a partnership with Accenture (NYSE: ACN) to develop AI solutions for federal agencies. On the commercial side, Palantir signed a deal with The Nuclear Company to develop and modernize nuclear power plants, as well as an agreement with The Joint Commission to use AI to manage accreditation and certification standards at hospitals and healthcare organizations. Palantir issued guidance for second-quarter revenue of $934 million to $938 million -- the midpoint of that would be a 38% increase from Q2 2024. Its full-year guidance is now in a range from $3.89 billion to $3.902 billion. The main argument for investing in Palantir today, of course, is the valuation. With a trailing price-to-earnings ratio (P/E) of 682 and a forward P/E of 269, Palantir is ungodly expensive. But that's not a deal-breaker for me. I keep remembering that Amazon had a P/E of more than 1,000 back in 2013 before people realized how important cloud computing and its Amazon Web Services platform would be. I think Palantir is like Amazon -- people are just starting to appreciate that Palantir is a transformative company that is changing the world and how businesses and governments operate. And when it reports earnings on Aug. 4, I think you're going to continue to see the stock soar. How to invest in Palantir I would never recommend that someone overinvest in a stock or put their entire nest egg into Palantir. But I do think it's a company that should be part of a portfolio. If you are worried about the inherent volatility that comes with a stock that's growing as quickly as Palantir (and has such a crazy valuation), I recommend using a dollar-cost averaging strategy to establish your position over time. Just be sure never to be overextended on any one stock -- even one as compelling as Palantir. Should you buy stock in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Bank of America is an advertising partner of Motley Fool Money. Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Accenture Plc, Amazon, Apple, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run. was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact: Justine O'Malley Protara 646-817-2836 Source: Protara TherapeuticsSign in to access your portfolio
